ライフサイエンスコーパス: Parkinson

1 Parkinson disease (PD) is a neurodegenerative disorder p

2 Parkinson's disease (PD) is a chronic and progressive ne

3 Parkinson's disease (PD) is a neurodegenerative disease

4 Parkinson's disease (PD) is associated with increased ir

5 Parkinson's disease (PD) is associated with the formatio

6 Parkinson's disease (PD) is characterized by a progressi

7 Parkinson's disease (PD) is characterized by slow, progr

8 Parkinson's disease (PD) is defined by the loss of dopam

9 Parkinson's disease (PD) is highly comorbid for a spectr

10 Parkinson's disease (PD) is the most common neurodegener

11 Parkinson's disease (PD) patients accumulate misfolded a

12 Parkinson's disease (PD) patients experience loss of nor

13 Parkinson's Disease (PD) psychosis refers to the spectru

14 Parkinson's disease and experimentally induced hemiparki

15 Parkinson's disease cases also increasingly reported anx

16 Parkinson's disease patients demonstrated an altered pat

17 Parkinson's Progression Markers Initiative (PPMI) is a l

18 N) activity and electroencephalography in 11 Parkinson's disease patients during a perceptual decisio

19 raging whole exome sequencing data from 1156 Parkinson's disease cases and 1679 control subjects.

20 re analyzed in 22 subthalamic nuclei from 13 Parkinson disease patients (57.5 +/- 5.9 years old, 4 fe

21 eveloped dementia with Lewy bodies (n = 13), Parkinson disease (n = 6), or multiple system atrophy (n

22 ), Creutzfeldt-Jakob disease (CJD, n = 239), Parkinson's disease (PD, n = 39), dementia with Lewy bod

23 Here, we sequenced the exomes of 244 Parkinson's patients selected from the Oxford Parkinson'

24 from deep brain stimulation electrodes in 9 Parkinson's disease patients.

25 rative conditions (Alzheimer's disease (AD), Parkinson's disease (PD) and Huntington's disease (HD),

26 everal brain disorders, including addiction, Parkinson's disease, Alzheimer's disease and schizophren

27 -9)), cognitive decline (P=5.3 x 10(-4)) and Parkinson's disease (P=8.6 x 10(-3)).

28 ght as a novel target for both addiction and Parkinson's disease (PD), as well as other emerging dise

29 gical diseases, including drug addiction and Parkinson's disease.

30 nked with neurodegeneration in Alzheimer and Parkinson disease, and many other pathologies.

31 mon human disorders, including Alzheimer and Parkinson diseases, type II diabetes, and a number of sy

32 patients with dementia with Lewy bodies and Parkinson disease shows that both diseases likely belong

33 h inflammation, increased risk of cancer and Parkinson disease, targeting C5aR1 may serve as a treatm

34 Prion diseases, like Alzheimer's disease and Parkinson disease, are rapidly progressive neurodegenera

35 ere loss, as seen in Alzheimer's disease and Parkinson's disease, to relatively little loss, as seen

36 e diseases including Alzheimer's disease and Parkinson's disease.

37 e diseases including Alzheimer's disease and Parkinson's disease.

38 , epilepsy, autism, Alzheimer's disease, and Parkinson's disease, and is considered a potential targe

39 ciation between immune-mediated diseases and Parkinson disease (PD).

40 k between synaptic endocytic dysfunction and Parkinson's disease.

41 neurone disease) (sporadic and familial) and Parkinson's Disease (PD).

42 of glioblastoma, traumatic brain injury, and Parkinson's disease.

43 so be seen in patients with Huntington's and Parkinson's disease who had received foetal neural allog

44 nerative diseases, including Alzheimer's and Parkinson's disease, are thought to spread to increasing

45 generative disorders such as Alzheimer's and Parkinson's diseases.

46 brain communication, such as Alzheimer's and Parkinson's diseases.

47 rodegenerative diseases like Alzheimer's and Parkinson's.

48 e pathways of Alzheimer's, Huntington's, and Parkinson's diseases and has been identified as a potent

49 seases (i.e., Alzheimer's, Huntington's, and Parkinson's diseases), carcinogenesis, stroke, intracere

50 / hyperactivity disorder, schizophrenia, and Parkinson's disease.

51 models for amyotrophic lateral sclerosis and Parkinson's disease, and show a partial rescue of the Pa

52 nvolved in amyotrophic lateral sclerosis and Parkinson's disease, respectively, using the small nine

53 ant drug candidates for nondopaminergic anti-Parkinson treatment.

54 2B (NR2B) dual antagonist and potential anti-Parkinson candidate compound, at 3.5 A resolution.

55 associated with neurologic disorders such as Parkinson disease-associated dementia and HIV-associated

56 syndromes to more common disorders, such as Parkinson's and Alzheimer's diseases.

57 cated in neurodegenerative disorders such as Parkinson's disease (PD), it is important to examine how

58 to the pathology of complex diseases such as Parkinson's Disease (PD).

59 h to study basal ganglia pathologies such as Parkinson's disease in silico.

60 ted approach to study BG pathologies such as Parkinson's disease in silico.

61 ified, its roles in other disorders, such as Parkinson's disease, are starting to emerge, and A2AR an

62 the treatment of synucleinopathies, such as Parkinson's disease, dementia with Lewy bodies, and mult

63 s well as neuropsychiatric disorders such as Parkinson's disease, schizophrenia, mood disorders, and

64 neurosurgery for movement disorders such as Parkinson's disease, tremor, and dystonia involves the p

65 as observed in age-related diseases such as Parkinson's disease.

66 rease in neurodegenerative disorders such as Parkinson's disease.

67 been reported to be associated with autism, Parkinson's disease and schizophrenia, respectively.

68 ilarities between dementia with Lewy bodies, Parkinson's disease, and Alzheimer's disease.

69 Dementia with Lewy bodies, Parkinson's disease, and Multiple System Atrophy are age

70 high specificity to dementia with Lewy body/Parkinson dementia.

71 a (SN) to neurodegenerative stressors causes Parkinson's disease (PD).

72 rexpression of mutant alpha-synuclein causes Parkinson's disease, presumably by driving neurodegenera

73 rt was followed-up for the onset of clinical Parkinson's disease using several overlapping modalities

74 Incident diagnoses of dementia, Parkinson's disease, and multiple sclerosis were ascerta

75 relationship with the incidence of dementia, Parkinson's disease, and multiple sclerosis.

76 ssociated with increased risk for developing Parkinson's disease (PD).

77 (GBA) confer a heightened risk of developing Parkinson's disease (PD) and other synucleinopathies, re

78 Methods Twenty patients with newly diagnosed Parkinson disease and 20 age-matched control subjects we

79 INTERPRETATION: In newly diagnosed Parkinson's disease, the occurrence of cognitive impairm

80 rative diseases such as Alzheimer's disease, Parkinson's disease, and Huntington's disease.

81 ression, schizophrenia, Alzheimer's disease, Parkinson's disease, and pain, provides convincing evide

82 elated diseases such as Alzheimer's disease, Parkinson's disease, multiple sclerosis and cardiovascul

83 is, neuromyelitis optica spectrum disorders, Parkinson disease, Alzheimer disease, Huntington disease

84 16 rest tremor recordings in tremor-dominant Parkinson's disease and 20 postural tremor recordings in

85 ognitive impairment (MCI) is common in early Parkinson's disease (PD).

86 corded from the subthalamic nucleus of eight Parkinson's disease patients during temporary lead exter

87 Eighteen Parkinson's disease patients learned through feedback ON

88 ful in identifying genes that cause familial Parkinson's disease (PD).

89 paminergic (mDA) neurons from stem cells for Parkinson's Disease (PD) therapy; however, production of

90 of 'awake' deep brain stimulation (DBS) for Parkinson's disease (PD) under local or general anaesthe

91 Deep brain stimulation (DBS) for Parkinson's disease is a highly effective treatment in c

92 represent the most prevalent risk factor for Parkinson's disease.

93 del is the most widely used animal model for Parkinson's disease (PD), it is known that nigrostriatal

94 .05 gave good classification performance for Parkinson's disease tremor and essential tremor, in both

95 Here we describe an alternative strategy for Parkinson's disease in which dopamine neurons are genera

96 Stem cell-based therapies for Parkinson's disease are moving into a new and exciting e

97 s approach may enable clinical therapies for Parkinson's disease by delivery of genes rather than cel

98 GF-beta signaling as a potential therapy for Parkinson's disease.

99 the most common neurosurgical treatment for Parkinson's disease motor symptoms.

100 s of purified iPSC-derived DaNs derived from Parkinson's disease (PD) patients carrying LRRK2 G2019S

101 tions in LRRK2 are a common cause of genetic Parkinson's disease (PD).

102 e responsible for the majority of hereditary Parkinson's disease cases.

103 tients were aged 25-75 years, had idiopathic Parkinson's disease as measured by Queen Square Brain Ba

104 In Parkinson disease (PD), mitochondrial dysfunction associ

105 In Parkinson's disease, a disease-specific physiomarker was

106 In Parkinson's disease, intracellular alpha-synuclein inclu

107 lly relevant neuroendocrine abnormalities in Parkinson's disease to highlight their role in overall p

108 ein, a protein forming amyloid aggregates in Parkinson's disease.

109 ependent relationships which were altered in Parkinson's patients in ways that resemble some but not

110 cus coeruleus, and ventral tegmental area in Parkinson disease (PD); the specific aims were (a) to st

111 thus opening new possible roles for betaS in Parkinson's and other neurodegenerative diseases.

112 Neuroendocrine abnormalities are common in Parkinson's disease (PD) and include disruption of melat

113 hypotheses for dopaminergic neuron death in Parkinson's disease.

114 ve symptomatic therapy for motor deficits in Parkinson's disease (PD).

115 compacta (SNpc) preferentially degenerate in Parkinson's disease (PD).

116 e posterior substantia nigra was elevated in Parkinson's disease compared to controls across single-

117 in (alpha-syn) aggregation is a key event in Parkinson's disease (PD).

118 -synuclein as a possibly causative factor in Parkinson's disease (PD).

119 oxicity are important etiological factors in Parkinson's disease (PD).

120 suggests that synapses are affected first in Parkinson's disease (PD).

121 ed striatal presynaptic dopamine function in Parkinson disease (PD) was performed.

122 , the Neuroprotection and Natural History in Parkinson Plus Syndromes Parkinson Plus Score and the Cl

123 n have been linked to neuronal impairment in Parkinson's disease and related neurodegenerative disord

124 ively correlated with clinical impairment in Parkinson's disease patients.

125 ts component alleles have been implicated in Parkinson disease and narcolepsy.

126 alpha-syn) toxicity, a protein implicated in Parkinson's Disease (PD) and other neurodegenerative dis

127 lphaS) forms round cytoplasmic inclusions in Parkinson's disease (PD) and dementia with Lewy bodies (

128 ld be a means of therapeutic intervention in Parkinson's disease and related conditions.

129 ents a major new avenue for investigation in Parkinson's disease, and effects on everyday symptoms sh

130 ment of levodopa-induced dyskinesia (LID) in Parkinson disease (PD) is an unmet need.

131 substantia nigra as a progression marker in Parkinson's disease, and describe the pattern of progres

132 ce the importance of lysosomal mechanisms in Parkinson's disease pathogenesis.

133 nuclein (alpha-SYN) is a central molecule in Parkinson's disease pathogenesis.

134 ntia nigra dopaminergic neurodegeneration in Parkinson's disease (PD), but how these pathways are lin

135 which is vulnerable to neurodegeneration in Parkinson's disease, and the calbindin-positive dorsal t

136 pars compacta (SNc) dopaminergic neurons in Parkinson's disease (PD).

137 in the cytoplasm of degenerating neurons in Parkinson's disease.

138 bute to the progression of neuropathology in Parkinson's disease (PD).

139 computational model for beta oscillations in Parkinson's disease (PD) can also account for complex pa

140 ew insight into mitochondrial pathologies in Parkinson's disease and provide new prospects for target

141 fy novel predictors for motor progression in Parkinson's disease.

142 Retinal degeneration is prominent in Parkinson's disease (PD), a neuromotor disorder associat

143 t DOPA decarboxylase (DDC), a key protein in Parkinson's disease.

144 ent of PARK2, a gene intensively reported in Parkinson's disease and schizophrenia research.

145 ammatory response plays an important role in Parkinson disease (PD).

146 a-Synuclein (alphaS) has a prominent role in Parkinson's disease (PD) pathology.

147 cally defined off-medication motor scores in Parkinson's disease, which were sustained beyond the per

148 ons complement prior neuroimaging studies in Parkinson disease patients, advancing our understanding

149 ses on recent human (18)F-FDG PET studies in Parkinson disease.

150 Freezing of gait is a disabling symptom in Parkinson disease and related disorders, but the brain r

151 insights into other behavioural symptoms in Parkinson's disease and addictions in the general popula

152 goal of dopamine cell replacement therapy in Parkinson disease (PD) is to provide clinical benefit me

153 models in the design of treatment trials in Parkinson's disease.

154 of toxic aggregates in neurons vulnerable in Parkinson's disease (PD), including dopaminergic neurons

155 directly comparing bicycling and walking in Parkinson disease patients with electrodes implanted in

156 i-site cohorts, and increased over 1 year in Parkinson's disease but not in controls at a single site

157 among patients with parkinsonism, including Parkinson disease (PD).

158 acular degeneration, traumatic brain injury, Parkinson's disease, and other neurodegenerations.

159 contribute to clinical differences in LRRK2 Parkinson's disease, including the emergence of non-moto

160 ion in LRRK2 mutation carriers with manifest Parkinson's disease and individuals with sporadic Parkin

161 LRRK2 mutation carriers without manifest Parkinson's disease (n=25) had greater (18)F-FDOPA uptak

162 but LRRK2 mutation carriers without manifest Parkinson's disease show increased serotonin transporter

163 2 mutation carriers with or without manifest Parkinson's disease, people with sporadic Parkinson's di

164 howed non-motor symptoms experienced by many Parkinson's disease patients including impaired cognitiv

165 Neurotoxins that mimic Parkinson's disease increased Cav1.3 function, decreased

166 ebo-controlled trial, patients with moderate Parkinson's disease were randomly assigned (1:1) to rece

167 e sex, and increased age, as well as a novel Parkinson's disease-specific epistatic interaction, all

168 ohort of, at baseline, patients with de novo Parkinson's disease (PD) compared with healthy controls

169 international longitudinal study of de novo Parkinson's disease.

170 enetic studies have shown the association of Parkinson's disease with alleles of the major histocompa

171 ese responses may explain the association of Parkinson's disease with specific major histocompatibili

172 ted in monogenic recessive familial cases of Parkinson's disease (PD).

173 incident cases of dementia, 31 577 cases of Parkinson's disease, and 9247 cases of multiple sclerosi

174 To understand the cause of Parkinson's disease (PD), it is important to determine t

175 tations are the most common genetic cause of Parkinson's disease, but LRRK2's normal physiological ro

176 ith an increased risk for the development of Parkinson's disease (PD).

177 ts and in particular with the development of Parkinson-like neuropathy.

178 ative disorders and is a hallmark feature of Parkinson's disease (PD) and PD-related diseases.

179 function and dementia are common features of Parkinson's disease (PD), causing significant disability

180 A major hallmark of Parkinson's disease (PD) is the presence of Lewy bodies

181 appearance of dyskinesia in the majority of Parkinson's disease patients.

182 recommendations on the medical management of Parkinson disease (PD) during Ramadan.

183 reams and is a potential prodromal marker of Parkinson's disease (PD).

184 ra is a valid, progression imaging marker of Parkinson's disease, which may be used in clinical trial

185 Progression markers of Parkinson's disease are crucial for successful therapeut

186 ral efficacy in 6-OHDA lesioned rat model of Parkinson diseases.

187 esigned to generate a more faithful model of Parkinson's disease by injecting human alpha-syn fibril

188 ate with graft outcome in an animal model of Parkinson's disease through gene expression analysis of

189 of dopaminergic neurons in a mouse model of Parkinson's disease using 1-methyl-4-phenyl-1,2,3,6-tetr

190 In a mouse model of Parkinson's disease, NeAL218 alone reprograms adult stri

191 egenerative symptoms in Drosophila models of Parkinson's and Huntington's diseases.

192 tibility, and the underlying neurobiology of Parkinson's disease.

193 gic innervation preceding the motor onset of Parkinson's disease.

194 While the pathogenesis of Parkinson's disease (PD) is incompletely understood, mit

195 itochondrial dysfunction and pathogenesis of Parkinson's disease (PD).

196 ion and neurotoxicity to the pathogenesis of Parkinson's disease and related alpha-synucleinopathies.

197 lay a primary role in the pathophysiology of Parkinson's disease (PD), and small molecules that count

198 milies with dominant inheritance patterns of Parkinson's disease, suggesting that it might confer a s

199 tablished and identified novel predictors of Parkinson's disease motor progression.

200 gait and posture, phenotypes reminiscent of Parkinson's disease, were evident when the mutation was

201 Studies suggest a greater risk of Parkinson's disease (PD) after traumatic brain injury (T

202 re to PM air pollution is related to risk of Parkinson's disease (PD) in the Health Professionals Fol

203 associated with a probable decreased risk of Parkinson's disease and type-2 diabetes and an increased

204 Following genetic screening of Parkinson's disease patients and healthy controls, we al

205 terations can be detected in early stages of Parkinson disease and that the entire intracranial visua

206 and striatal binding ratio in a subgroup of Parkinson's disease who had undergone both diffusion and

207 The motor symptoms of Parkinson's disease (PD) are linked to abnormally correl

208 ) is an emerging target for the treatment of Parkinson's disease (PD).

209 2AR-selective compounds for the treatment of Parkinson's disease.

210 ceptor that is a target for the treatment of Parkinson's disease.

211 However, the few available studies on Parkinson disease (PD) have conflicting results, compris

212 ociated with autosomal recessive early-onset Parkinson's disease (PD).

213 ctional protein in a patient with late onset Parkinson's disease.

214 55-85 years (about 2.2 million; dementia or Parkinson's disease cohort) who resided in Ontario, Cana

215 arkinson's patients selected from the Oxford Parkinson's Disease Centre Discovery Cohort and, after q

216 o cross-sectional PET studies at the Pacific Parkinson's Research Centre in Vancouver, BC, Canada.

217 with neurodegenerative disease, particularly Parkinson-like syndrome and dystonia.

218 non-motor features in the 23 years preceding Parkinson's disease diagnosis by performing a nested cas

219 ears before diagnosis onwards, prediagnostic Parkinson's disease cases more commonly had problems in

220 n conclusion, in patients with prediagnostic Parkinson's disease, impairments in instrumental daily a

221 PARK7 are a rare cause of familial recessive Parkinson's disease (PD), but growing evidence suggests

222 degenerative diseases including Alzheimer's, Parkinson's and motor neuron disease.

223 yotrophic lateral sclerosis and Alzheimer's, Parkinson's, and Huntington's diseases, our findings ide

224 neurodegenerative diseases like Alzheimer's, Parkinson's, prion diseases, etc.

225 es and proteins associated with Alzheimer's, Parkinson's, type 2 diabetes and prion diseases.

226 cantly reduced in Alzheimer's, Huntington's, Parkinson's diseases.

227 er's disease, amyotrophic lateral sclerosis, Parkinson's disease, and Huntington's disease.

228 er's disease, amyotrophic lateral sclerosis, Parkinson's disease, and the prototypic neuroinflammator

229 Sporadic Parkinson's disease has been proposed to develop after i

230 ssociated with risk of familial and sporadic Parkinson's disease (PD).

231 phaSyn) is the major gene linked to sporadic Parkinson's disease (PD), whereas the G209A (p.A53T) alp

232 findings with those in people with sporadic Parkinson's disease and age-matched healthy controls.

233 mutation carriers, individuals with sporadic Parkinson's disease, and age-matched healthy controls se

234 st Parkinson's disease, people with sporadic Parkinson's disease, and age-matched healthy controls, a

235 ation carriers, 13 individuals with sporadic Parkinson's disease, and nine healthy controls.

236 nson's disease and individuals with sporadic Parkinson's disease, but LRRK2 mutation carriers without

237 r binding than did individuals with sporadic Parkinson's disease, with (18)F-FDOPA uptake comparable

238 gy-independent manner.SIGNIFICANCE STATEMENT Parkinson's disease is characterized by progressive moto

239 Natural History in Parkinson Plus Syndromes Parkinson Plus Score and the Clinical Global Impression

240 eveloped clinically defined synucleinopathy (Parkinson's disease in 11, dementia with Lewy bodies in

241 The Parkinson's Progression Markers Initiative is a prospect

242 ine vs 7.33 [3.52] after dim-red LT) and the Parkinson's Disease Sleep Scale (97.24 [22.49] at baseli

243 catecholaminergic neurons, thus avoiding the Parkinson-like phenotype associated with full dopaminerg

244 's disease, and show a partial rescue of the Parkinson's phenotype through drug treatment.

245 ha-SYN) is a major pathologic contributor to Parkinson's disease (PD).

246 nts suffering from dopamine depletion due to Parkinson's disease were selectively impaired in reward

247 kinase 2 (LRRK2) and alpha-synuclein lead to Parkinson's disease (PD).

248 d in mitochondrial homeostasis and linked to Parkinson's disease.

249 neurons is a promising approach to treating Parkinson's disease.

250 ent cohort comprising a further 55 tremulous Parkinson's disease and essential tremor recordings.

251 of cellular dysfunctions which may underlie Parkinson's disease (PD) progression.

252 change in PD clinical scale scores (Unified Parkinson's Disease Rating Scale) and DAT imaging during

253 ce in the Movement Disorders Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) motor subsc

254 Scale, and Movement Disorder Society Unified Parkinson's Disease Rating Scale motor scores; 0.76, 0.6

255 symptoms (Movement Disorder Society Unified Parkinson's Disease Rating Scale, MDS-UPDRS III), fitnes

256 s from the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) parts II an

257 ical improvement (motor score of the Unified Parkinson Disease Rating Scale [UPDRS]).

258 JFK Coma Recovery Scale-Revised, the Unified Parkinson Disease Rating Scale, and the Burke-Fahn-Marsd

259 analyses, and correlations with the Unified Parkinson's Disease Rating Scale scores were tested.

260 rior, and whole SNpc correlated with Unified Parkinson's Disease Rating Scale scores (r(2) = 0.25, 0.

261 nuclein family has long been associated with Parkinson's disease and dementia.

262 icates that the CNR2 gene is associated with Parkinson's disease and substance use disorders.

263 Neurotoxins associated with Parkinson's disease fully engages ER-p38 MAPK-CMA pathwa

264 abetes mellitus, a-synuclein associated with Parkinson's disease, transthyretin V30M mutant associate

265 olded proteins such as those associated with Parkinson's, Alzheimer's, and CJD diseases.

266 e disorder gene variants in association with Parkinson's disease risk.

267 No association was found with Parkinson's disease or multiple sclerosis.

268 hway.SIGNIFICANCE STATEMENT Individuals with Parkinson's disease dementia often suffer a characterist

269 a higher incidence of dementia, but not with Parkinson's disease or multiple sclerosis.

270 ied PINK1, which is studied in patients with Parkinson and cancer (especially melanoma).

271 structural brain connectome in patients with Parkinson disease (PD) and mild cognitive impairment (MC

272 visual hallucinations (VHs) in patients with Parkinson disease (PD) by analyzing whole-brain resting-

273 ld cognitive impairment (MCI), patients with Parkinson disease (PD), and young and older healthy volu

274 iated with levodopa therapy in patients with Parkinson disease (PD).

275 disabling nonmotor symptoms in patients with Parkinson disease (PD).

276 kinesias occur in up to 80% of patients with Parkinson's after a few years of chronic treatment.

277 Here, we tested the ability of patients with Parkinson's disease (PD) to maximize monetary rewards an

278 e of serotonergic pathology in patients with Parkinson's disease (PD).

279 he time of clinical diagnosis, patients with Parkinson's disease already have a wide range of motor a

280 s in free water in 103 de novo patients with Parkinson's disease and 49 controls; (ii) 2- and 4-year

281 13-35 Hz) is commonly found in patients with Parkinson's disease and can be suppressed by dopaminergi

282 ar and clinical variables from patients with Parkinson's disease and healthy controls to construct an

283 apeutic interventions to treat patients with Parkinson's disease and impulse control disorders have s

284 In patients with Parkinson's disease and impulse control disorders, impai

285 tions used in the treatment of patients with Parkinson's disease are associated with motor and non-mo

286 sing data from nine cohorts of patients with Parkinson's disease from North America and Europe assess

287 n free water in a subset of 46 patients with Parkinson's disease imaged at baseline, 12, 24, and 48 m

288 shopping occur in about 17% of patients with Parkinson's disease on dopamine agonists.

289 390 patients with Parkinson's disease recruited between July 1, 2010, and

290 3200 patients with Parkinson's disease who were longitudinally assessed wit

291 In patients with Parkinson's disease, elevations in beta activity (13-35

292 BACKGROUND & AIMS: In most patients with Parkinson's disease, gastrointestinal (GI) dysfunctions,

293 netic Resonance Imaging in ten patients with Parkinson's disease.

294 nitive health or impairment in patients with Parkinson's disease.

295 People with Parkinson's disease can show premotor neurochemical chan

296 y increased risk for melanoma in people with Parkinson's disease.

297 The mortality among persons with Parkinson disease is only moderately increased compared

298 that contribute to falls among subjects with Parkinson's disease (PD).

299 ubjects and a group of elderly subjects with Parkinson's disease using an event-related functional MR

300 In the past 5 years, Parkinson's disease cases developed additional motor fea